michelcarroll/llama2-earnings-stock-prediction-fine-tune huggingface dataset:
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, that was quite a bit, Ann. We will try to get to it. You make very good use of your one question and one follow-up. So why don't we start first to some of the things from a demand perspective because Barb's got some good data on that, that are supportive of strong demand?

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
So I think, Daniel, look, so two parts there. One is the fact that patients are getting to paid so quickly gives patients and doctors a lot of confidence. That's something that they worried about, and we're really pleased with the progress there. And then the -- what I just mentioned about patients converting from free product to paid product, that's going to happen over time.
And it is a tailwind. It's not an instant tailwind, but it's something that we expect to make progress over the coming months, contributing to that steady growth in patients and revenue going forward.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
This is Ernest. From my point of view, 2022 is going to be a formative year. And we are confident, if not hopeful, that 2023 is going to provide some significantly good news, which we can't comment on now because they're in process. Bob, do you want to add anything?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thank you. Good morning, and I'll let go all the congrats, Jim, and welcome Jacinth. But wanted to just touch on the capacity piece and maybe two things. One, is for the Pepperoni expansion in 2Q. Any sense of when within 2Q that might come? Should we really just count on any bump up there in the second half? But I guess the bigger question is, how does the guidance -- how does the capacity expansion fit in guidance and maybe getting at if there is any delays, would that potentially impact what the outlook might be?

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. So I think what we've talked about on previous calls, as we think of the casualty and specialty kind of rolling 10-year blocks. And do I think the rate that we're getting in most of that book today is adequate. I'd say the answer is, yes, in most classes. The issue is, if you take the 10-year block, you're not at a REITs that allows that block to achieve adequate returns. So I think there is more rate that should come into those portfolios. Because it's been a long -- great has been going for a couple of years, but it was a long period of rate reductions. And that, on a 10-year rolling basis had a pretty heavy impact on insurers and reinsurers. And right now, I see, particularly with the growth that we're able to achieve, we are very quickly approaching rate adequacy for the full 10-year block, and a lot of that is because we've been able to so effectively grow into the improving market.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, I think it's really about that market share gain that I talked about and it is growing the kids' business, which I said 35 percentage points to the total market is what we experienced, which is pretty amazing from a growth standpoint. And then what we're seeing is, as I said in the quarter, it was the second largest acquisition -- customer acquisition quarter in the history of the company. And that comes by having athletic and kids' and the digital investments we're making. So we are seeing that it's introducing us to a new consumer and it's adding to the business we were already doing with that family.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Richard, I'll start out. This is John, and then maybe Greg can add some commentary on the end of that. But our anticipation is that this is on track to close by the end of this year or at the end of this year. As you may know from our previous discussions, we do have a 364-day loan that we have access to. And we're frankly evaluating numerous different financing options that we've been looking at. We hope to do a fair amount of that in the first quarter. It's possible with blackout periods, etc., that some of that may get done in the second quarter. And it's even possible that some of that gets done in this calendar year. So Greg, any other color on that?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, to answer your first question and what we're seeing year-to-date in January is consistent with our expectations, which is not surprising since we're giving the guidance here at the end of January. But we're pleased with the trajectory that the Refined Product demand is in the markets we serve. On the second part of your question, I don't have that handy. I think the number is 3% overall. But I don't have the breakdown in front of me on -- and maybe Jeff does.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, I think right now, for the rest of the year, the theater leases are more on a percentage rent deal, so they really kick in more next year.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. No, there absolutely is opportunity price to value with Optimal Blue, we're doing that. And like we're doing, and we talk about constantly, it's really getting value pricing. We're driving tremendous value for our clients and just benefiting by some of that. So, that work is under way. It's going well. We're fortunate, obviously, that in that space our clients are doing exceptionally well in the origination space. So, that's really not proving to be a challenge for us right now.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
You're Welcome.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
You are welcome.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes, I think at this point where we're comfortable saying is, we've got activity going on with a handful of customers and exactly handicapping where we install what, I think is still, not clear to me. We don't have a lot of bandwidth, right. So we will be at some point, limited by what we can bring up when, and customers will have to see how important this is to them, and who wants to make sure we have capacity for them.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Question, I wanted to see if you guys could give us an indication of what you're thinking for services growth in Q2? And then I have a follow-up on that.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks very much, Nancy, just following up on your last comment there answering Mike's question. For these shortages that you're talking about the 20 million in 1Q, the 20 million or 25 million in Q2 those are in backlog, right? It's not that, those are out in the ether someplace, those are in your backlog and in those order numbers that you referenced as being strong in the quarter?

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. Really good question, David. And, candidly, we were a bit surprised by the strength of the capital equipment market. I think if you go back to a couple of calls ago, I was probably pretty -- I'm probably negative about the potential for capital. And I don't know that we were way off except for the fact that we did pretty well with both -- some of our newer stuff, which has gone pretty well for us.
We had a 10% quarter on equipment and that was, both US and international. So, we had good strength in our cataract equipment, particularly strong with CENTURION and our new entry LEGION in the international markets, which is a lower priced, but advanced fluidics kind of a phaco machine, performed very well there.
Vitrec was also double-digit growth for, both US and international and we got a small bump in the US, of course, for procedural eyedrops where we had a bit of an outage. But I would probably just say that the overall effort I think internationally is up on equipment. And in some markets, I think we may have underestimated the desire and drive for new equipment, read China and some of the emerging markets.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks very much. Good morning. And thanks for taking my question. I just wanted to follow-up on your comment around the acquisition opportunities. Steve, one of the things that was anticipated that with PAMA, there'd be a lot of pressure and you'd see more acquisition opportunities. With PAMA now being pushed out, does that change anything, number one? And number two, when we think about reimbursement as we've been talking about for molecular tests, etc.. I would think a lot of these labs have done well during this period of time. Does that change what their expectations are at all around what their business is worth as we think about acquisition opportunities?

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure. I think that there -- if you think about DRAM, what they've really been pushing on, and it's very difficult, as you know, to do it, is to continue scaling. And we do think that there's going to be some EUV that comes in. But there's no question that there's scaling happening.
And of course, that drives more process control intensity. The other thing that's pretty clear in DRAM is the overlay requirements continue to get more and more challenging. So we're seeing increased -- trying to understand of how to squeeze more capability out of the lithography sets that they've got. And then we do see some, as I say, EUV adoption.
So we think there'll be incrementally more focus on our more advanced optical inspection tools to be able to support that. So that's what we're seeing as a trend. It's not necessarily, obviously, as EUV-heavy as what we'd see in foundry/logic, but there is some element of EUV in there. Does that answer your question, Patrick?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I would just reiterate what Steve said in our prepared comments, Jade, we're looking at double-digit EPS growth and double-digit EBITDA growth. And your model will tell you what your model is going to tell you. But we're very bullish about our company and about our growth opportunities. I think Steve gave great specifics on where we think we get uplift in EBITDA as it relates to transaction volumes on brokerage, on debt and brokerage on properties. And that's what we're providing to the market.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
You are welcome.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hi Ryan.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. I mean, we're quite fortunate at NovoCure and that our platform, Tumor Treating Fields offers so much opportunity. It offers the opportunity to treat virtually all solid tumor cancers, and it offers the opportunity to be combined with all the emerging pharmacological therapies, and we know we can continue to improve it through technological innovation. And those are essentially our highest priorities.
In response to your specific question, advancing our late-stage pipeline is among the highest priorities in the company. There is no preference for new indications. The indications that we have in the late stage are large. The trials are based on science and Phase 2 data that are extremely promising.
And our goal is to get those trials done, evaluate the data, and get the therapy, as I said, to patients. That said, and with different teams, we're also not going to stop there. We're going to backfill -- I'm not sure backfill is the right verb here, but we're going to continue to fill the pipeline. That is a different set of teams.
And that's one of the things our financial strength has allowed, which is the ability to do both. But it's not as if one group is thinking on Monday about recruiting the late-stage trial, and then they have to switch on Tuesday to think about what's going to come next. The teams that are focused on the late-stage trials are dedicated to recruiting those trials.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
They're high.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Amanda, this is Debbie. Good morning. I just want to welcome you. I think, this is your first time participating in our call. And we want to welcome you. But, I'll turn the hard work over to Justin to answer your question.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. We had a very good SaaS quarter. So that's in the prepared remarks. Across the board, every one of our SaaS businesses grew double-digit -- in total, grew double-digits, but I think every one of them grew their SaaS business at double digits. So, very good position in which to do that. And we expect to grow SaaS this year double-digits. So we want to continue to invest in those businesses. You also heard several examples in the prepared remarks of how in the prepared remarks of how FBS is really generating value in those businesses today I think, as well. So, I think that's how we feel like the performing bookings were good as well. So we feel like we're in a very good position. Relative to software, in general, we're starting to see some of the on-site services start to come back at a more accelerated rate, although still a long way to go. But as we said that Accruent actually grew all up in the quarter. I think that's a good showing, if you will. Gordian, flat. Both of those on the back of service getting better, still not great, but we like the trend. So I think overall, we're in a very good position across the board. And we're -- some of the investments we just talked about our investments in those businesses as well.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. I agree with you. So nine months ago I thought there might be an opportunity to use the strength of our balance sheet, our liquidity, like we did really back in the last crisis, in 2009-2010, we really took advantage of a pretty chaotic environment in banking to substantially grow the firm. And I think I did mention that, that could be a possibility. It really wasn't the Federal Reserve stepped in quickly. And as I said by really our June quarter announcement, we were saying to the Street, we saw a pretty big and certain build in M&A and activity.
I would say at this point, recruiting is pretty good. There are people who want to move. I continue to believe the boutique environment and some of the dynamism around the innovations that we're able to show including our capital markets activity and some of the things we're doing are still leading people to search out our platform. But it's not unusual. I'd say it's very similar to the prior years.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Good Morning Matt.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I don't think that we have communicated a date for the CMD, Giulio. If there is anything, we'll speak about that.

    Prediction (one of UP, DOWN, SAME): DOWN